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Proton beam therapy (PBT) is a potential new alternative to treatment with pho-
ton radiotherapy that may reduce the risk of late toxicity and secondary cancer,
especially for pediatric tumors. The goal of this study was to evaluate the long-
term benefits of PBT in cancer survivors. A retrospective observational study of
pediatric patients who received PBT was performed at four institutions in Japan.
Of 343 patients, 62 were followed up for 5 or more years. These patients
included 40 males and 22 females, and had a median age of 10 years (range:
0–19 years) at the time of treatment. The irradiation dose ranged from 10.8 to
81.2 GyE (median: 50.4 GyE). The median follow-up period was 8.1 years (5.0–
31.2 years). The 5-, 10- and 20-year rates for grade 2 or higher late toxicities were
18%, 35% and 45%, respectively, and those for grade 3 or higher late toxicities
were 6%, 17% and 17% respectively. Univariate analysis showed that the irradi-
ated site (head and neck, brain) was significantly associated with late toxicities.
No malignant secondary tumors occurred within the irradiated field. The 10- and
20-year cumulative rates for all secondary tumors, malignant secondary tumors,
and malignant nonhematologic secondary tumors were 8% and 16%, 5% and
13%, and 3% and 11%, respectively. Our data indicate that PBT has the potential
to reduce the risk of late mortality and secondary malignancy. Longer follow-up
is needed to confirm the benefits of PBT for pediatric tumors.
R ecent progress in treatment of pediatric tumors has improvedsurvival and almost 70% of patients can now be cured.(1)
However, late toxicities of radiotherapy may occur in long-term
survivors, and reduction of quality of life due to growth and
development retardation and secondary cancer is a significant
problem for pediatric patients.(2,3) Armstrong et al.(4) showed
that mortality due to the original malignancy begins to plateau
beyond 20 years, while death from non-recurrence causes
increases. Between 15 and 30 years, the cumulative mortality
attributable to the primary disease only increases from 6.3% to
7.8%, while that due to non-recurrence causes increases from
2.0% to 7.0%. Schoot et al.(5) found that 77% of long term sur-
vivors (median follow-up 10.5 years, n = 31) after radiotherapy
for pediatric head and neck tumor experience late toxicities of
grade 3 or 4; Ducassou et al.(6) showed that 23% of survivors
for 5 or more years (n = 22) after radiotherapy for neuroblas-
toma experienced late toxicities of grade 3 or more; and Perwein
et al.(7) found that 50% of long-term survivors (median follow-
up 7.4 years, n = 16) after radiotherapy for neuroblastoma
experienced late toxicity of grade 3 or more.
Proton beam therapy (PBT) is likely to have reduced risks
of late toxicity and secondary cancer, and Sethi et al.(8) found
a 10-year cumulative incidence of 0% for all in-field secondary
malignancies after PBT. However, long-term follow-up is diffi-
cult because of tumor recurrence or cases lost in follow-up,
and this results in limited information on late toxicity after
radiotherapy. This is particularly true for PBT because of the
relatively short history of the technique. Here, we evaluated
late toxicity in long-term follow-up after PBT in a multicenter
study in Japan.
All data were published in a previous report.(9) The current
manuscript examines late toxicity in long-term survivors.
Materials and Methods
A retrospective observational study in pediatric patients who
received PBT was performed at four institutions in Japan.
Institutional Review Boards approved the study at all insti-
tutes. All 343 patients aged <20 years old at the time of
receiving PBT at these sites from January 1983 to August
2014 were initially enrolled. Previously, we report the over-
view of this retrospective observational study.(9) In the report
we mainly analyzed overall survival and late toxicities of all
patients. The study showed that main purpose of PBT was to
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reduce the risk of late toxicity and secondary cancer. We con-
sider that long-term follow-up is an essential condition to eval-
uate the risk of late toxicity and secondary cancer. However,
the study included a number of short follow-up patients. So
here we perform the secondary analysis focused on long-term
survivors.
Of these patients, 62 were followed-up for 5 or more years.
There were 40 males and 22 females, and the median age at
treatment was 10 years old (range: 0–19). The irradiated site
were head and neck (n = 24), brain (n = 22), body trunk
(n = 9) and others (n = 7). The irradiation dose ranged from
10.8 to 81.2 GyE (median: 50.4 GyE). The median follow-up
period in the 62 patients was 8.1 years (range: 5.0–31.2 years).
Statistical analysis. Rates for late toxicities and secondary
tumors were calculated using the Kaplan–Meier method. A
log-rank test was used to examine differences for age, gender,
irradiated site, irradiation dose, and irradiation volume. All
analyses were performed with SPSS v. 11.0 (SPSS Inc., Chi-
cago, IL, USA). Toxicities were graded using the Common
Terminology Criteria for Adverse Events ver. 3.0.
Results
At the final follow-up, 22 of 62 patients had late toxicities of
grade 2 or more, with a median time from the first day of PBT
to the day of diagnosis of the late toxicity of 4.5 years (range:
0.8–28.2 years). Four of the 22 patients had multiple late toxi-
cities of grade 2 or more, and 6 had deformities of grade 2 or
more, with all deformities occurring in patients irradiated in
the head and neck or brain. The 5-, 10- and 20-year rates of
late toxicities of grade 2 or more were 18% (95% CI 8–27%),
35% (95% CI 22–49%) and 45% (95% CI 24–65%) respec-
tively, and those for late toxicities of grade 3 or more were
6% (95% CI 0–13%), 17% (95% CI 5–28%) and 17% (95%
CI 5–28%), respectively (Fig. 1).
Univariate analysis showed that the irradiated site (head and
neck, brain) was significantly associated with late toxicity
(Fig. 2). The 5- and 10-year late toxicity rates after head and
neck or brain irradiation were 22% (95% CI 11–33%) and
42% (95% CI 27–57%) at grade 2 or more and 8% (95% CI
0–16%) and 20% (95% CI 7–32%) at grade 3 or more. For
patients who did not have a head and neck or brain tumor, no
late toxicity of grade 2 or more occurred within 20 years. Age
(>10 or ≤10 years old), gender, irradiation dose (>40 or ≤40
GyE) and irradiation volumes (<100 or ≤100 mL) were not
significantly associated with late toxicity. Multivariate analysis
showed no significant difference in late toxicities for any fac-
tors. Six patients had late toxicity after the age of 20. And 11
of 30 late toxicities occurred after the age of 20. Figure 3
presents the relationship between onset age and Grade of late
toxicity.
As previously reported several patients had a secondary
tumor.(9) In this report, four of 62 patients had a secondary
tumor after PBT, including three malignant tumors (osteosar-
coma, thyroid cancer and acute myelocytic leukemia (AML))
and one case of pituitary adenoma. All malignant secondary
tumors occurred outside the irradiated field, with only pituitary
adenoma occurring within the irradiated field. The 10- and 20-
year cumulative incidences for all secondary tumors (osteosar-
coma, thyroid cancer, AML and pituitary adenoma), malignant
secondary tumors (osteosarcoma, thyroid cancer and AML)
and malignant solid secondary tumors (osteosarcoma and
thyroid cancer) were 8% (95% CI 0–18%) and 16% (95% CI
0–33%), 5% (95% CI 0–11%) and 13% (95% CI 0–29%), and
3% (95% CI 0–9%) and 11%(95% CI 0–27%), respectively.
The incidences of all malignant secondary cancers and in-field
malignant secondary cancers are shown in Figure 4.
Discussion
Comprehensive data from this study have been reported else-
where, but this previous analysis included cases with a variety
of tumors and a short follow-up time.(9) The advantages of
PBT for pediatric patients are likely to be fewer late adverse
events and a reduced risk secondary malignancy, since com-
parisons of dose distribution between PBT and photon radio-
therapy indicate a decreased dose to normal tissue in
PBT.(10,11) Late toxicity has been found in long-term follow-up
of pediatric patients after photon radiotherapy. In an analysis
of 17 patients who survived for at least 5 years (median
20 years) after radiotherapy for head and neck pediatric rhab-
domyosarcoma, Paulino et al. found late effects of treatment
in 11 cases with facial growth retardation, nine with neuroen-
docrine dysfunction, nine with visual/orbital problems, seven
Fig. 1. Incidence of late adverse events in all patients.
Fig. 2. Incidence of late adverse events in cases of head and neck or
brain tumor.
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with dental abnormalities, and six with hearing loss.(12) The
severity was unclear, but these data show a high rate of late
toxicity and similar late toxicities to those found in our
patients (deformation, neuroendocrine dysfunction, and hearing
impairment).
Our data showed 10-year late toxicity rates after PBT for
head and neck cancer of 42% at grade 2 or more and 20% at
grade 3 or more, respectively. Based on a simple comparison
with the above rates for photon radiotherapy, PBT appears to
reduce the risk of late toxicity. In a preliminary study of PBT
for pediatric rhabdomyosarcoma, Ladra et al. found rates of
late toxicity of 28% for grade 2 and 7% for grade 3, but it
should be noted that the cases included truncal site tumors and
the follow-up period was relatively short.(13) In patients with
parameningeal rhabdomyosarcoma, Childs et al.(14) found that
PBT in a relatively small group of 10 patients reduced long-
term toxicities compared with a historical control group treated
with photon radiotherapy. At this time, more than a third of
late toxicities occurred age 20 or older. This result indicates
that a routine follow-up is needed in adult life to evaluate the
precise late effect of PBT.
There is also limited information on secondary malignancy
after PBT.(8) Some reports have shown that PBT can reduce
the risk of secondary malignancy,(15,16) and recently Sethi
et al. showed that the 10-year cumulative incidences of sec-
ondary tumors in survivors of retinoblastoma were significantly
lower in those treated with PBT compared to photon therapy
for both in-field (0% vs 14%) and all (5% vs 14%) secondary
malignancies. In our analysis, the 10-year cumulative rates of
in-field and all secondary malignancies were 0% and 5%,
respectively, which are exactly the same as those in Sethi
et al. Stringent comparison with photon radiotherapy is diffi-
cult because of variation in patient backgrounds, but these data
suggest that PBT has a lower risk of radiotherapy-induced
malignancy.
The risk of subsequent malignancy continues to increase
after 40 years old,(17) and at age 55 the cumulative inci-
dence of new malignancy reaches 16.3%. This shows that
radiotherapy is a risk factor for late mortality and subse-
quent malignancy. Improved outcomes of pediatric tumors
requires increased long-term survival after radiotherapy,
and our data indicate that PBT has the potential to reduce
the risk of late mortality and subsequent malignancy.
However, the follow-up period was still short and the
number of patients was insufficient for comparison with
photon historical data, in particular. Longer follow-up is
needed to confirm these advantages of PBT for pediatric
tumors.
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Fig. 3. Figure between brackets indicates kind of late toxicity. A, Angiostenosis; Al, Alopecia; B, Brain injury; D, Deformity; Dy, Dysphagia; G,
Growth hormone deficiency; H, Hearing impairment; He, Headache; O, Otitis media; P, Pneumonitis; Pr, Precocious puberty; S, Seizure; T, Thyroid
dysfunction; V, Visual impairment; X, Xerostomia. Four patients (P1, P2, P3, P4) had multiple late toxicities.
Fig. 4. Incidences of all malignant secondary cancers and in-field
malignant secondary cancers.
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